Medical affairs is going through a meaningful shift. Once positioned primarily as a support function, it is now widely recognised as a strategic partner shaping scientific, clinical and commercial decisions across the product lifecycle.^1–3 Below are ten key shifts defining the future of medical affairs and what teams should understand to adapt, contribute and create impact in an evolving healthcare landscape.

1. Medical affairs as a strategic partner across the organisation

As medical affairs takes on a broader role across the organisation, its value as a strategic partner increasingly stems from contributing context and judgement to decision-making. Through close engagement with emerging evidence and ongoing dialogue with healthcare professionals (HCPs), patients and payers, medical affairs offers insight into real-world interpretations and applications of science.^2,4–6

2. Healthcare complexity and expectations reshape medical affairs

Increasing scientific complexity, rapid growth in available data and evolving expectations from clinicians, payers and patients are fundamentally changing the medical affairs environment.^4–6 These shifts place greater emphasis on clear, balanced scientific communication that supports understanding and appropriate use of emerging evidence.

3. Towards a more integrated evidence ecosystem

A defining element of the future medical affairs landscape is the move towards more integrated and continuous evidence generation. Rather than relying on sequential or functionally siloed studies, organisations are adopting rapid evidence cycles that combine real-world evidence, health economics and outcomes research, and Phase 3b/4 studies.^4,5,7

For teams, this means designing evidence strategies that can evolve as new questions emerge, clinical practice changes and stakeholder needs develop.

4. Data-driven insight reshapes evidence generation

Advanced analytics and artificial intelligence (AI) are transforming how evidence is generated, interpreted and applied. IQVIA reports that more than 80% of life sciences organisations now prioritise AI investment within core functions.

Within medical affairs, analytics support earlier identification of evidence gaps, more efficient synthesis of complex data and improved use of real-world data in evidence planning. In practice, these capabilities enable teams to adjust study strategies as new information becomes available and to generate insights that inform decisions across development, launch and in-market phases.^9–11

5. Designing evidence with stakeholders in mind

As evidence generation becomes more dynamic, it must also become more intentionally aligned with stakeholder needs. Clinicians look for relevance to everyday practice, payers focus on outcomes and value, and patients seek clarity that connects evidence to lived experience.^5–7 The key is to ensure evidence is relevant, credible and useful from the outset.

6. The rise of multi-channel engagement

Scientific engagement is no longer defined by individual interactions or isolated channels. Medical Affairs teams are combining face-to-face engagement with digital platforms, webinars and on-demand formats to reflect how stakeholders prefer to access information and manage time constraints.^5,10,11

This creates greater flexibility and reach, enabling scientific exchange to adapt across regions, roles and therapeutic areas.

7. Scientific conversations are becoming more decentralised

Scientific conversations increasingly go beyond traditional peer-to-peer models. Digital thought leaders, clinician-influencers and patient advocates play a growing role in shaping how information is shared and discussed, particularly in rare disease settings where digital communities often provide essential access to knowledge and peer support.^2,6,10 For Medical Affairs teams, this means engaging with a broader and more diverse set of voices across channels.

8. Omnichannel coordination is critical to effective engagement

The challenge is no longer expanding the number of channels but how effectively those channels are connected. Omnichannel approaches allow stakeholders to experience communication as coherent and continuous rather than fragmented. Think beyond individual touchpoints and design engagement as a connected experience.

9. Integrated insight supports clearer patient pathways

More connected engagement provides deeper insight into care delivery. By bringing together signals from real-world data, field medical interactions and digital engagement, teams can identify where variation and delays occur along the patient journey, such as late diagnosis, inconsistent referral patterns or barriers to specialist care.^6,12

10. Continuous, role-specific training underpins future impact

As the role of medical affairs evolves, so must the capabilities that underpin its impact. Teams are expected to work with more complex data, support a broader range of engagement models and contribute more actively to strategic discussions.^2,11

Continuous, role-specific training becomes a practical requirement. Approaches using structured and digitally enabled training help ensure capabilities are built consistently over time and across regions, supporting teams in maintaining their strategic contribution.^2,5

Bringing medical affairs into focus

Medical affairs sits at the point where evidence, engagement and decision-making come together. Organisations best prepared for the future will be those that invest not only in data and tools, but also in the capabilities needed to interpret information, engage stakeholders consistently and adapt to changing clinical and organisational contexts.

At Cognite, we support our Medical Affairs team members across evidence communication, omnichannel and stakeholder engagement, and training to help bring their science to life.

If you’d like to explore how these trends could shape your medical affairs strategy, we’d be happy to continue the conversation. Feel free to reach out to Joanne Pearson, Medical Affairs Lead, at joanne.pearson@cognite.co.

References

1. Pharmaceutical Executive. Pharma medical affairs: a blueprint for future. 2019. Available at: https://www.pharmexec.com/view/pharma-medical-affairs-blueprint-future [accessed March 2026].
2. The future of medical affairs position paper. 2024. Available at: https://medicalaffairs.org/position-paper-future-medical-affairs-2030 [accessed March 2026].
3. Has medical affairs reached ‘strategic pillar’ standing? 2023. Available at: https://www.emjreviews.com/emj-gold/article/has-medical-affairs-reached-strategic-pillar-standing/ [accessed March 2026].
4. A vision for medical affairs in 2025. 2019. Available at: https://www.mckinsey.com/industries/life-sciences/our-insights/a-vision-for-medical-affairs-in-2025  [accessed March 2026].
5. A vision for medical affairs 2030: five priorities for patient impact. 2023. Available at: https://www.mckinsey.com/industries/life-sciences/our-insights/a-vision-for-medical-affairs-2030-five-priorities-for-patient-impact [accessed March 2026].
6. Executive vision: medical affairs in a changing society. 2023. Available at: https://medicalaffairs.org/innovate-articles-executive-vision-changing-society/ [accessed March 2026].
7. Strategic integrated evidence generation planning: company and non-company sponsored research. 2025. Available at: EVIDENCE-GENERATION-Standards-and-Guidance-2-11-2025.pdf [accessed March 2026].
8. AI in life sciences commercialisation white paper. 2024. Available at: ai-in-life-sciences-commercialization-white-paper.pdf  [accessed March 2026].
9. Preparing for the future of medical affairs. 2024. Available at: https://medicalaffairsspecialist.org/blog/preparing-for-the-future-of-medical-affairs [accessed March 2026].
10. Future of external education position paper. 2024. Available at: https://medicalaffairs.org/wp-content/uploads/2024/06/Future-of-EE-2030-WP-Final-Draft-June-2024.pdf [accessed March 2026].
11. The evolving role of medical affairs in APAC. 2018. Available at: The-evolving-Role-of-Medical-Affairs-in-APAC.pdf [accessed March 2026].
12. Evolving role of medical affairs: unlocking pathway optimisation. 2025. Available at: Evolving Role of Medical Affairs: Unlocking Pathway Optimization [accessed March 2026].